Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims are unsupported or materially overstated relative to the provided label excerpts (especially grapefruit composition/quantitative effects and clinical outcome causality). High-priority safety labeling sections (e.g., contraindications, boxed warnings) were not provided for verification.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication and can be used in patients at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia, with drug therapy as an adjunct to diet.
1 INDICATIONS AND USAGE; 12.1 Mechanism of Action (context of lipid-altering therapy)
Lipitor reduces LDL production.
12.1 Mechanism of Action ("also reduces LDL production")
Grapefruit juice can increase plasma concentrations of atorvastatin.
7.2 Grapefruit Juice ("can increase plasma concentrations of atorvastatin")
Grapefruit juice components inhibit CYP3A4 and can increase atorvastatin levels.
7.2 Grapefruit Juice ("components that inhibit CYP 3A4 and can increase plasma concentrations")
Unsupported Statements
Grapefruit contains furanocoumarins, specifically bergamottin and dihydroxybergamottin.
No such grapefruit composition details are present in the provided label excerpts.
CYP3A4 is responsible for metabolizing many medications, including Lipitor.
Provided sections do not state that CYP3A4 metabolizes many medications or atorvastatin.
CYP3A4 is responsible for metabolizing blood thinners, immunosuppressants, and certain antibiotics.
Provided sections do not state CYP3A4 metabolism of these specific medication classes.
Grapefruit-induced increases in Lipitor levels can lead to interactions with other medications including blood thinners, immunosuppressants, and certain antibiotics.
The provided grapefruit interaction section does not describe interactions with specific medication classes; it only addresses increased atorvastatin concentrations.
Grapefruit juice increased atorvastatin (Lipitor) levels by 40% in healthy volunteers.
No quantitative result is included in the provided excerpts.
Grapefruit juice increased atorvastatin (Lipitor) levels by 60% in patients with hypercholesterolemia.
No quantitative result is included in the provided excerpts.
Patients should avoid consuming grapefruit or grapefruit juice while taking Lipitor.
The provided label excerpt warns about increased concentrations with excessive grapefruit intake but does not explicitly use an "avoid" instruction.
Oranges, lemons, and limes are safe to consume while taking Lipitor.
No discussion of these foods is present in the provided label excerpts.
Grapefruit-free juice does not contain grapefruit or grapefruit juice.
No discussion of grapefruit-free juice definitions or safety is present in the provided label excerpts.
It is not recommended to take Lipitor if you consume grapefruit or grapefruit juice, because the risks of adverse effects are increased.
The provided label excerpts do not state an "it is not recommended" directive based on grapefruit intake.
Grapefruit can interact with many medications, including blood thinners, immunosuppressants, and certain antibiotics.
No such list or statement is present in the provided label excerpts.
Reducing plaque buildup decreases the risk of heart attacks and strokes.
No explicit label support is provided in the excerpts for heart attack/stroke outcome claims or a plaque-buildup causal chain.
Grapefruit furanocoumarins inhibit the activity of the CYP3A4 enzyme.
The excerpts support CYP3A4 inhibition by grapefruit juice components, but do not identify furanocoumarins specifically.
Grapefruit contains compounds that can inhibit the CYP3A4 enzyme, potentially leading to increased levels of Lipitor.
Supported as written by 7.2, so this item should not be here; included only if strict attribution to "compounds"/"furanocoumarins" is required—however 7.2 supports "components" generally.
Contradictions
Important Omissions
FDA-label verification for contraindications, boxed warning content, and other high-priority safety sections (e.g., Contraindications (4), Boxed Warning, Pregnancy/Lactation, Pediatric Use) was not possible because these sections were not included in the provided label excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several grapefruit-related mechanistic/clinical causality and quantitative claims are unsupported or overstated in the provided excerpts; additionally, key safety labeling sections were not provided for audit, limiting confidence that recommendations match FDA labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported or exaggerated claims (grapefruit composition, quantitative increases, and clinical outcome causality), plus inability to verify high-priority safety labeling due to missing label sections.
Suggested Improvement
Restrict grapefruit-related claims to what the provided label states (CYP3A4 inhibition by grapefruit juice components and increased atorvastatin concentrations, especially with excessive intake >1.2 L/day). Remove quantitative (40%/60%) and food-specific assertions not present in the provided excerpts, and avoid causal outcome statements (plaque/MI/stroke) not explicitly supported.